Clinical Trial Update: Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab [Phase 2]

View source ↗

Summary

A Phase 2 trial of selective IMRT with concurrent panitumumab for locally advanced head and neck cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: WITHDRAWN